Xinhua Pharmaceutical announced that in April 2025, the company submitted the marketing license registration application data for sacubatl valsartan tablets to the Drug Evaluation Center of the State Drug Administration and was accepted; in October 2026, it obtained the “Drug Registration Certificate” approved and issued by the State Drug Administration. The review concluded that registration was approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.